How does HTA for orphan drugs differ across Europe?New research looks at the factors that speed up and slow down HTA appraisals for rare disease medicines Share XHow does HTA for orphan drugs differ across Europe?https://pharmaphorum.com/views-analysis-market-access/how-does-hta-for-orphan-drugs-differ-across-europe/
England is risking its own opioid epidemic, says PHEHundreds of thousands of people in England are at risk of dependency on prescription medicines like opioid painkillers, Share XEngland is risking its own opioid epidemic, says PHEhttps://pharmaphorum.com/news/england-is-risking-its-own-opioid-epidemic-says-phe/
NHS England gets commercialNHS England is no longer the new kid on the block, taking up its role in 2013. In Share XNHS England gets commercialhttps://deep-dive.pharmaphorum.com/magazine/access-and-commercialisation/nhs-england-commercial-framework-vpas/
The shadow of Brexit on speed of accessNo-one can miss the ongoing saga that is the UK’s exit from the European Union (EU). The uncertainties Share XThe shadow of Brexit on speed of accesshttps://pharmaphorum.com/views-analysis-market-access/the-shadow-of-brexit-on-speed-of-access/
The new CDF – Navigating Cancer Drug Access in EnglandOn July 29th 2016, the new process in England for cancer drugs seeking license went live – changing Share XThe new CDF – Navigating Cancer Drug Access in Englandhttps://pharmaphorum.com/partner-content-oncology/new-cdf-navigating-cancer-drug-access-england/
Available on-demand: The Price is Right? – Delivering UK access for niche patient populations With challenges to highly priced rare disease medicines and the Cancer Drug Fund evolving again – what Share XAvailable on-demand: The Price is Right? – Delivering UK access for niche patient populationshttps://pharmaphorum.com/debates-insight-market-access/live-webinar-the-price-is-right-uk-niche-market-access/
